124 related articles for article (PubMed ID: 12404910)
21. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
22. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
[TBL] [Abstract][Full Text] [Related]
24. Germ-line alterations in MSR1 gene and prostate cancer risk.
Seppälä EH; Ikonen T; Autio V; Rökman A; Mononen N; Matikainen MP; Tammela TL; Schleutker J
Clin Cancer Res; 2003 Nov; 9(14):5252-6. PubMed ID: 14614006
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
27. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
28. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
29. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
30. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
31. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer.
Lindmark F; Jonsson BA; Bergh A; Stattin P; Zheng SL; Meyers DA; Xu J; Grönberg H
Prostate; 2004 May; 59(2):132-40. PubMed ID: 15042613
[TBL] [Abstract][Full Text] [Related]
33. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
34. Segregation analysis of 389 Icelandic pedigrees with Breast and prostate cancer.
Baffoe-Bonnie AB; Kiemeney LA; Beaty TH; Bailey-Wilson JE; Schnell AH; Sigvaldason H; Olafsdóttir G; Tryggvadóttir L; Tulinius H
Genet Epidemiol; 2002 Nov; 23(4):349-63. PubMed ID: 12432503
[TBL] [Abstract][Full Text] [Related]
35. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
36. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
37. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
38. Hereditary prostate cancer: clinical characteristics and survival.
Bratt O; Damber JE; Emanuelsson M; Grönberg H
J Urol; 2002 Jun; 167(6):2423-6. PubMed ID: 11992050
[TBL] [Abstract][Full Text] [Related]
39. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
40. Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families.
Bock CH; Peyser PA; Montie JE; Cooney KA
Prostate; 2005 Jun; 64(1):60-6. PubMed ID: 15651090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]